FDA Posts Warning on Compounded Semaglutide Products, Citing Reports of Adverse Events
Compounded versions of semaglutide, often sold online, may contain salt versions of the molecule and are not evaluated by the FDA for safety or efficacy.
The Long COVID Neuro Differential Dx: Sometimes Tricky, Always Nuanced
Coauthor of a new multidisciplinary guidance statement on assessment of neurologic sequelae of long COVID highlights a consensus on steps to rule the condition out.
Long COVID Typically Presents in Symptom Clusters, Rarely as a Single Complaint, Expert Explains
A Feinberg School of Medicine physiatrist with long experience assessing long COVID talks specifically about common neurologic sequelae of the infection.
Friday's 5 Quotes for Primary Care 6-2-2023
The world's first RSV vaccine and the virus surveillance that is missing, PCPs missing opportunities to treat obesity, T2D linked to subclinical CVD, and more news.
Pfizer Wins FDA Approval for Vaccine against RSV in Older Adults
The FDA's decision was based on data from the pivotal phase 3 RENOIR trial, which demonstrated the efficacy, immunogenicity, and safety of Abrysvo in adults aged ≥60 years.
Long COVID was Apparent by Summer 2020 and in a Wide Range of Patients
Symptoms of long COVID were apparent by the summer of 2020, said physiatrist Dr Leslie Rydberg, coauthor of new consensus guidelines on management of neurologic sequelae.
One in 3 US Adults with T2D Shows Evidence of Subclinical CVD Based on Cardiac Biomarkers
As indicated by levels of 2 common biomarkers of cardiac injury, 33.4% of US adults with T2D showed evidence of undetected CVD vs only 16.1% of those without T2D.
FDA Approves SGLT-2/1 Inhibitor Sotagliflozin, Grants Broad Heart Failure Indication
The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.
Robust RSV Surveillance Data Will be Key to Getting US Clinicians Comfortable with New Adult Vaccine
Immunize.org's Dr Kelly Moore says that without clear surveillance data on RSV, particularly on hospitalizations, clinicians may hesitate to commit office resources to administration.
Are US Seniors Ready for an RSV Vaccine? Consider the Lessons of COVID-19, says Dr Kelly Moore
Low awareness of RSV in adults and misperceptions about the goal of vaccination aren't new challenges, says Kelly Moore, MD, MPH, Immunize.org president and CEO.
FDA Approves Rx Nalmefene Nasal Spray to Reverse Opioid Overdose
In a unique pharmacodynamic study, nalmefene demonstrated rapid reversal of respiratory depression from the synthetic opioid remifentanil and sustained duration of action.
Weight Loss of 15% with Oral Semaglutide 50 mg Equal to SQ Wegovy: Late Stage Clinical Trial
Efficacy of the daily pill met the standard now established by the once-weekly injection of 15% loss of baseline bodyweight in adults with overweight or obesity, says Novo Nordisk.
Migraine without Aura May Increase Stroke Risk for Women Taking Combined Hormonal Contraceptives
The findings contradict published clinical guidelines that warn against use of estrogen-containing birth control by women who have migraine with aura.
GSK Adult RSV Vaxx: Public Health Expert Reviews Topics for ACIP Meeting in June
Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.
Statin Therapy May be Protective Against Stroke in People with Atrial Fibrillation: New Study
Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.
FDA Advisory Group Votes in Favor of Pfizer Investigational Maternal RSV Vaccine Candidate
The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.
First RSV Vaccine Brings "Sense of Relief" to Public Health Experts, Says Immunize.org President
Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."
First Opioid Rx Leads to Long-term Use in 1 of 5 with Rheumatic or Musculoskeletal Disorders
Patients with rheumatoid arthritis and fibromyalgia were at the greatest risk of transitioning to long-term opioid use 1 year after a first prescription, a new study found.
FDA Grants Dapagliflozin Label Expansion for Treatment of Full Spectrum of Heart Failure
The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.
9 New Studies on Women's Health in Recognition of Women's Health Week 2023
Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.
3 Things for Primary Care to Remember About Physical Medicine and Rehabilitation
Scott Laker, MD, vice president of the AAPM&R, offers 3 thoughts on what primary care clinicians should think of when they think about PM&R.
Friday's 5 Quotes for Primary Care 5-12-2023
USPSTF says start mammograms 10 years earlier, OTC contraceptive coming soon, another antiobesity drug in the wings, and 2 more weekly updates of note.
FDA Approves Brexpiprazole for Agitation Associated with Alzheimer Dementia
Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.
Medication Can't Do It All, Says Obesity and Weight Management Expert
Dr Caroline Apovian reminds primary care clinicians who care for patients with obesity that diet and lifestyle counseling are essential for maximum results.
Primary Care and Physiatry: Complementary Tools for Full Recovery from Injury
The partnership between primary care and PM&R is a tool in each specialty's tool box, with the patient's return to full function the shared goal.
Oral Contraceptive Gets Unanimous Recommendation for OTC Use from FDA Advisory Panel
Opill, a progestin-only oral contraceptive, if approved by the FDA, would be the first an only form of birth control in the US available without a physician's prescription.
Investigational Antiobesity Drug from Boehringer Ingelheim Meets Primary Endpoint in Phase 2 Trial
The dual GIP/GLP-1 receptor agonist was associated with a nearly 15% reduction in body weight in adults with overweight/obesity and without type 2 diabetes.
Denosumab Superior to Alendronate for Reduction of Postmenopausal Fracture Risk in Real-world Study
Denosumab reduced RR of fracture vs alendronate across fracture types, eg, by 36% for hip fracture, by 43% for nonvertebral fractures, and by 30% for vertebral fractures.
Concussion Patients are Getting Younger: Bad News, Good News
A diagnosis of concussion in an 8-year-old who plays weekend soccer is, on its face, bad news; the good news is that 15 years ago, it might have gone unnoticed, untreated.
USPSTF: Begin Breast Cancer Screening at Age 40 (Not 50) Years for All Women
The lower recommended starting age for screening reflects rising cancer diagnoses among younger women and persistently high mortality rates among Black women.